Supply of AGRIPPAL inactivated influenza (surface antigen) vaccine injection pre-filled syringe (with needle) by Novartis Vaccines and Diagnostics Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the importation, supply, and advertising of therapeutic goods in Australia, aiming to ensure that these goods are of an acceptable standard and do not pose an unacceptable risk to health and safety. This legislation was introduced to address the need for a comprehensive framework governing the quality, efficacy, and safety of therapeutic goods, including medicines, medical devices, and other health-related products. Enacted by the Parliament of Australia, the Act aims to protect public health by ensuring that therapeutic goods available in the market meet the required standards. In the case of the 2012 notice, the Department of Health and Ageing granted consent under sections 14 and 14A of the Act for specific deviations from the Therapeutic Goods Order No 69 concerning labelling requirements for a particular vaccine product due to practical constraints of the product's physical dimensions.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation and control of therapeutic goods in Australia, encompassing a wide range of products including medicines, medical devices, blood and blood components, tissues, and vaccines. This Act applies to all entities and persons involved in the manufacturing, importation, supply, and advertising of therapeutic goods within Australia, ensuring that these goods meet specified standards for quality, safety, and efficacy. The Act's jurisdiction extends across the Commonwealth, and it applies to all states and territories of Australia, thereby providing a unified regulatory framework for therapeutic goods nationwide. However, the Act includes certain exclusions and exemptions, particularly for goods used for personal or domestic purposes, or for research and development activities under specific conditions. The application of the Act can be further defined and extended through subordinate instruments such as regulations and orders, which provide detailed specifications and requirements for various aspects of therapeutic goods regulation.

Key Provisions

The Therapeutic Goods Act 1989, specifically under sections 14 and 14A, provides the legal framework for granting consent to certain activities that may otherwise contravene regulatory requirements. In this instance, the delegate of the Secretary of the Department of Health and Ageing, on 22 November 2012, gave consent to Novartis Vaccines and Diagnostics Pty Ltd to supply the AGRIPPAL inactivated influenza vaccine, which is a pre-filled syringe with a needle, identified by Australian Register number 144670. This consent acknowledges that the product does not conform to specific labelling requirements as outlined in the Therapeutic Goods Order No 69 (section 14(1)). The Act permits this consent when it is evident that compliance with certain standards would be impractical due to physical constraints, such as the limited space on the syringe label. Specifically, the consent allows the company to deviate from clause 3(1)b(ii) of the Therapeutic Goods Order No 69, which stipulates a minimum letter height for the Sponsor's name on the syringe label, and from clause 3(2)b, which requires the listing of all active ingredients on the label. These deviations are due to the practical limitations imposed by the physical size of the syringe label (section 14A(1)). Entities governed by the Therapeutic Goods Act, such as Novartis Vaccines and Diagnostics Pty Ltd, are obligated to ensure that their products meet the regulatory standards unless they have obtained specific consent under sections 14 and 14A. In this case, the company must adhere to all other labelling and supply requirements, while also maintaining compliance with the Act's overarching provisions concerning the safety and quality of therapeutic goods. The delegate’s consent under these sections is conditional and specifically tailored to the circumstances where full compliance is not feasible due to practical limitations (section 14(2)). In terms of legal consequences, breaches of the Therapeutic Goods Act can lead to various civil and criminal penalties. For instance, supplying non-compliant therapeutic goods can result in fines, imprisonment, or both, depending on the severity and intent behind the breach. The maximum penalties for contravening the Act can include fines of up to $2,200,000 for corporations and lesser amounts for individuals, alongside potential imprisonment terms for serious offences. Furthermore, ongoing non-compliance can lead to the revocation of the therapeutic goods registration and further legal action by regulatory authorities (section 14(3)).